Skip to main content
SpringerLink
Log in

Psoriasisarthritis

Psoriatic arthritis

  • Originalien
  • Published:
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen Aims and scope

Zusammenfassung

Die Psoriasisarthritis präsentiert ein sehr heterogenes klinisches Bild und stellt in der täglichen Praxis große Herausforderungen an Diagnosestellung und Therapieentscheidung. Die Enthesitis dürfte eine zentrale Rolle bei dieser entzündlichen Autoimmunerkrankung spielen.

Die European League Against Rheumatism (EULAR) empfiehlt eine Treat-to-target-Vorgehensweise im Sinne einer konsequenten Therapieüberwachung und -anpassung in definierten Zeitabständen. Stufenweise soll nach dem Einsatz von nichtsteroidalen Antirheumatika (NSAR) eine Therapie mit csDMARDs und bDMARDs („conventional synthetic [cs] and biological [b] disease-modifying antirheumatic drugs“) wie TNF-alpha-Blocker, Interleukin-17- und Interleukin-12/23-Inhibitoren erfolgen. Die „Group for Research and Assessment of Psoriasis and Psoriatic Arthritis“ (GRAPPA) hingegen empfiehlt ein individuelles therapeutisches Vorgehen je nach betroffener Domäne.

Abstract

Psoriatic arthritis presents a heterogeneous clinical picture and constitutes a great diagnostic and therapeutic challenge in daily practice. Enthesitis seems to play a central role in this inflammatory autoimmune disorder.

The European League Against Rheumatism (EULAR) recommends a treat-to-target approach in terms of consistent treatment monitoring and adjustment at defined intervals. Gradually, administration of non-steroidal anti-rheumatics should be followed by treatment with conventional synthetic and biological disease-modifying anti-rheumatic drugs (csDMARDs and bDMARDs) such as TNF-alpha-blockers, interleukin-17, and interleukin-12/23 inhibitors. However, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommends an individual therapeutic approach depending on the affected area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Coates LC, Ritchlin CT, Kavanaugh AF (2014) GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol 41(6):1237–1239 (Jun)

    Article  PubMed  Google Scholar 

  2. Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C (1991) Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 30(4):245–250 (Aug)

    Article  PubMed  CAS  Google Scholar 

  3. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med 62(238):127–141

    PubMed  CAS  Google Scholar 

  4. Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42(12):1460–1468

    Article  CAS  Google Scholar 

  5. Popescu C, Zofotă S, Bojincă V, Ionescu R (2013) Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis—cross-sectional study and literature review. J Med Life 6(4):376–382

    PubMed  PubMed Central  CAS  Google Scholar 

  6. Bowes J, Ashcroft J, Dand N et al (2017) Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis 76(10):1774–1779 (Oct)

    Article  PubMed  PubMed Central  Google Scholar 

  7. Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 136(12):896–907 (Jun)

    Article  PubMed  Google Scholar 

  8. Dhir V, Aggarwal A (2013) Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol 44(2):141–148 (Apr)

    Article  PubMed  Google Scholar 

  9. Schett G, Lories RJ, D’Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13(12):731–741

    Article  PubMed  CAS  Google Scholar 

  10. Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957–970

    Article  PubMed  Google Scholar 

  11. Simon D, Faustini F, Kleyer A et al (2016) Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis 75(4):660–666

    Article  PubMed  CAS  Google Scholar 

  12. Lories RJ, McInnes IB (2012) Primed for inflammation: enthesis-resident T cells. Nat Med 18(7):1018–1019 (Jul)

    Article  PubMed  CAS  Google Scholar 

  13. Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–57

    Article  PubMed  CAS  Google Scholar 

  14. Polachek A, Li S, Chandran V, Gladman DD (2017) Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken) 69(11):1685–1691

    Article  Google Scholar 

  15. Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD (2017) The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol 69(3):622–629

    Article  PubMed  Google Scholar 

  16. Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A (2017) Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 69(1):51–57 (Jan)

    Article  Google Scholar 

  17. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510 (Mar)

    Article  PubMed  CAS  Google Scholar 

  18. Guyatt GH, Oxman AD, Kunz R et al (2008) Incorporating considerations of resources use into grading recommendations. BMJ 336:1170–1173

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ogdie A, Schwartzman S, Husni ME (2015) Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 27:118–126

    Article  PubMed  Google Scholar 

  20. Di Minno MND, Ambrosino P, Lupoli R et al (2015) Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Ann Med 47:346–353

    Article  PubMed  CAS  Google Scholar 

  21. Smolen JS, Braun J, Dougados M et al (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6–16

    Article  PubMed  Google Scholar 

  22. Schoels M, Aletaha D, Alasti F et al (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811–818

    Article  PubMed  Google Scholar 

  23. Coates LC, Navarro-Coy N, Brown SR et al (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101

    Article  PubMed  PubMed Central  Google Scholar 

  24. Coates LC, Moverley AR, McParland L et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489–2498

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bond SJ, Farewell VT, Schentag CT et al (2007) Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 66:370–376

    Article  PubMed  Google Scholar 

  26. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778–783

    Article  PubMed  CAS  Google Scholar 

  27. Cresswell L, Chandran V, Farewell VT et al (2011) Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 70:305–308

    Article  PubMed  Google Scholar 

  28. Brockbank JE, Stein M, Schentag CT et al (2005) Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 64:188–190

    Article  PubMed  CAS  Google Scholar 

  29. Simon P, Pfoehler C, Bergner R et al (2012) Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 30:45–50

    PubMed  CAS  Google Scholar 

  30. Gladman DD, Mease PJ, Choy EHS et al (2010) Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 12:R113

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Ramiro S, Smolen JS, Landewé R et al (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 75(3):490–498 (Mar)

    Article  PubMed  CAS  Google Scholar 

  32. Curtis JR, Beukelman T, Onofrei A et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 69:43–47

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Ash Z, Gaujoux-Viala C, Gossec L et al (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71:319–326

    Article  PubMed  CAS  Google Scholar 

  34. Eder L, Chandran V, Ueng J et al (2010) Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 49:1367–1373

    Article  PubMed  Google Scholar 

  35. Eder L, Thavaneswaran A, Chandran V et al (2014) Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis 73:1007–1011

    Article  PubMed  CAS  Google Scholar 

  36. Young MS, Horn EJ, Cather JC (2011) The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol 7(1):9–13 (Jan)

    Article  PubMed  CAS  Google Scholar 

  37. Langley RG, Elewski BE, Lebwohl M (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338

    Article  PubMed  CAS  Google Scholar 

  38. Mease PJ, Van der Heijde D, Ritchlin CT (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79–87

    Article  PubMed  CAS  Google Scholar 

  39. Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071

    PubMed  Google Scholar 

  40. Mease PJ, Gottlieb AB, van der Heijde D (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550–1558

    Article  PubMed  PubMed Central  Google Scholar 

  41. Mease P, Hall S, FitzGerald O (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537–1550

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheuma-Zentrum Wien-Oberlaa, Kurbadstraße 14, 1100, Wien, Österreich

    Johannes Resch-Passini &  Peter Spellitz

Authors
  1. Johannes Resch-Passini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Spellitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Resch-Passini.

Ethics declarations

Interessenkonflikt

J. Resch-Passini und P. Spellitz geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Resch-Passini, J., Spellitz, P. Psoriasisarthritis. J. Miner. Stoffwechs. Muskuloskelet. Erkrank. 25, 60–66 (2018). https://doi.org/10.1007/s41970-018-0036-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41970-018-0036-3

Schlüsselwörter

Keywords

Search

Navigation